title: Ischemic preconditioning (IP) of the liver as a safe and protective technique against ischemia/reperfusion injury (IRI).
abstract: The aim of the study was to evaluate safety and efficacy of IP in LT, particularly in marginal grafts. From 2007 to 2008, 75 LT donors were randomized to receive IP (IP+) or not (IP-). Considering the graft quality, we divided the main groups in two subgroups (marg+/marg-). IP was performed by 10-min inflow occlusion (Pringle maneuver utilizing a toruniquet). Donor variables considered were gender, age, AST/ALT, ischemia time and steatosis. Recipient variables were gender, age, indication to LT and MELD/CHILD/UNOS score. AST/ALT levels, INR, bilirubin, lactic acid, bile output on postoperative days 1, 3 and 7 were evaluated. Histological analysis was performed evaluating necrosis/steatosis, hepatocyte swelling, PMN infiltration and councilman bodies. Thirty patients received IP+ liver. No differences were seen between groups considering recipient and donor variables. Liver function and AST/ALT levels showed no significant differences between the main two groups. Marginal IP+ showed lower AST levels on day1 compared with untreated marginal livers (936.35 vs. 1268.23; p = 0.026). IP+ livers showed a significant reduction of moderate-severe hepatocyte swelling (33.3% vs. 65.9%; p = 0.043). IP+ patients had a significant reduction of positive early microbiological investigations (36.7% vs. 57.1%; p = 0.042). In our experience IP was safe also in marginal donors, showing a protective role against IRI.
authors.affiliation: Liver Transplantation Centre, Molinette Hospital, Turin, Italy. afranchello@molinette.piemonte.it
authors.forename: A
authors.initials: A
authors.lastname: Franchello
authors.forename: N
authors.initials: N
authors.lastname: Gilbo
authors.forename: E
authors.initials: E
authors.lastname: David
authors.forename: A
authors.initials: A
authors.lastname: Ricchiuti
authors.forename: R
authors.initials: R
authors.lastname: Romagnoli
authors.forename: E
authors.initials: E
authors.lastname: Cerutti
authors.forename: M
authors.initials: M
authors.lastname: Salizzoni
mesh_terms: D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D005260:Female; D006085:Graft Survival; D006801:Humans; D019194:Ischemic Preconditioning / Q000379:methods*; D008099:Liver / Q000098:blood supply* / Q000293:injuries* / Q000502:physiology; D016031:Liver Transplantation / Q000379:methods* / Q000502:physiology; D008297:Male; D008875:Middle Aged; D015427:Reperfusion Injury / Q000517:prevention & control*; D014019:Tissue Donors; D020858:Tissue and Organ Harvesting / Q000379:methods*
chemical_list: D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase